Canaccord Genuity Adjusting Estimates on Imris Inc. (IMRS); Bookings and Margins Up
Tweet Send to a FriendGet Alerts IMRS Hot Sheet
Price: $2.66 -1.85%
Rating Summary:
2 Buy, 1 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 25 | New: 24
Rating Summary:
2 Buy, 1 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 25 | New: 24
Trade IMRS Now!
Canaccord Genuity maintains a 'Buy' on Imris Inc. (NASDAQ: IMRS) price target of $4.50.
Analyst, Jason R. Mills, said, "Q1 bookings of $24M exceeded our $22M estimate, and management set Q2 revenue guidance at $15-16M, higher than our estimate of $11.5M heading into the call, as backlog conversion is expected to accelerate. Notably, management continues to be very bullish about its sales funnel. We maintain our rating and price target, albeit we realize that multiple expansion may be challenging near term given the lumpy nature of new order bookings."
"We’re raising our FY12 sales estimate to $57.7M from $57.4M but lowering our LPS estimate to $(0.50) from $(0.42) based on higher technology development, R&D and regulatory spending, which impacts both GM and OpEx. That said, we remain focused on bookings trends as the primary leading indicator of the business’ health."
For an analyst ratings summary and ratings history on Imris Inc. click here. For more ratings news on Imris Inc. click here.
Shares of Imris Inc. closed at $3.20 yesterday, with a 52 week range of $2.26-$8.20.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Analyst, Jason R. Mills, said, "Q1 bookings of $24M exceeded our $22M estimate, and management set Q2 revenue guidance at $15-16M, higher than our estimate of $11.5M heading into the call, as backlog conversion is expected to accelerate. Notably, management continues to be very bullish about its sales funnel. We maintain our rating and price target, albeit we realize that multiple expansion may be challenging near term given the lumpy nature of new order bookings."
"We’re raising our FY12 sales estimate to $57.7M from $57.4M but lowering our LPS estimate to $(0.50) from $(0.42) based on higher technology development, R&D and regulatory spending, which impacts both GM and OpEx. That said, we remain focused on bookings trends as the primary leading indicator of the business’ health."
For an analyst ratings summary and ratings history on Imris Inc. click here. For more ratings news on Imris Inc. click here.
Shares of Imris Inc. closed at $3.20 yesterday, with a 52 week range of $2.26-$8.20.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Jefferies Raises Numbers on hhgregg (HGG), But Remains on Sidelines
- Goldman Sachs Upgrades Meritor (MTOR) to Buy
- Goldman Sachs Upgrades Abbott Labs (ABT) to Buy
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS Change, Analyst EPS View
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
